循環器内科学

Medicine & Life Sciences

1. Heart Failure 100%
2. Myocardial Infarction 87%
3. Percutaneous Coronary Intervention 70%
4. Coronary Artery Disease 68%
5. Atrial Fibrillation 68%
6. Acute Coronary Syndrome 56%
7. Stents 54%
8. pitavastatin 51%
9. Computed Tomography Angiography 43%
10. Japan 42%
11. Hydroxymethylglutaryl-CoA Reductase Inhibitors 42%
12. Heart-Assist Devices 39%
13. Optical Coherence Tomography 39%
14. Brain Natriuretic Peptide 37%
15. Coronary Angiography 37%
16. Coronary Vessels 34%
17. Myocarditis 31%
18. Registries 28%
19. Echocardiography 28%
20. Lipids 26%
21. Atherosclerotic Plaques 26%
22. Myocardial Perfusion Imaging 25%
23. Hemorrhage 24%
24. Therapeutics 23%
25. Stroke Volume 22%
26. Heart Transplantation 21%
27. Chronic Renal Insufficiency 21%
28. Mortality 21%
29. Heart 20%
30. Non-ST Elevated Myocardial Infarction 20%
31. Everolimus 20%
32. ST Elevation Myocardial Infarction 20%
33. Thrombosis 20%
34. Atorvastatin 19%
35. Confidence Intervals 19%
36. Glomerular Filtration Rate 19%
37. Eicosapentaenoic Acid 18%
38. Pathologic Constriction 18%
39. Rivaroxaban 18%
40. Coronavirus 18%
41. Extracorporeal Membrane Oxygenation 17%
42. Cardiology 17%
43. Anticoagulants 16%
44. Perfusion 16%
45. Tomography 16%
46. Incidence 16%
47. LDL Cholesterol 16%
48. Left Ventricular Dysfunction 16%
49. Sirolimus 16%
50. Unstable Angina 15%
51. Serum 14%
52. Hospital Mortality 14%
53. Equipment and Supplies 14%
54. Sarcoidosis 13%
55. Acute Kidney Injury 13%
56. Biomarkers 13%
57. Safety 13%
58. Transplants 13%
59. Stroke 13%
60. Cardiac Rehabilitation 13%
61. Subarachnoid Hemorrhage 13%
62. Exercise 13%
63. Multicenter Studies 13%
64. Coronary Stenosis 13%
65. Troponin 13%
66. Drug-Eluting Stents 13%
67. Angiography 12%
68. Single-Photon Emission-Computed Tomography 12%
69. Elderly 12%
70. Blood Vessels 12%
71. Frailty 11%
72. Atherosclerosis 11%
73. Pressure 11%
74. iodofiltic acid 11%
75. Warfarin 11%
76. Cause of Death 11%
77. Stable Angina 11%
78. Angiotensin Receptor Antagonists 11%
79. Cardiogenic Shock 11%
80. Troponin I 11%
81. ROC Curve 11%
82. Heart Diseases 10%
83. Cohort Studies 10%
84. Secondary Prevention 10%
85. Regression Analysis 10%
86. Population 10%
87. Pandemics 10%
88. Hypertrophic Cardiomyopathy 10%
89. Catheter Ablation 10%
90. Prospective Studies 10%
91. pentadecanoic acid 9%
92. Electrocardiography 9%
93. Fatty Acid-Binding Proteins 9%
94. Peripheral Arterial Disease 9%
95. Left Ventricular Function 9%
96. Hospitalization 9%
97. Kidney 9%
98. Area Under Curve 9%
99. azilsartan 9%
100. Inflammation 9%